INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on February 2, 2022, reporting events occurring on January 31, 2022. The Company is incorporated in Nevada and its principal executive offices are located in Sarasota, Florida.
Key Financial Metrics and Transaction Details
The filing details a partial closing of a previously announced equity financing with Paradigm Opportunities Fund, LP.
- Transaction Type: Unregistered sale of equity securities (Item 3.02) and entry into a material definitive agreement (Item 1.01).
- Shares Sold (Initial Closing): 94,623 shares of common stock.
- Gross Proceeds Received: $315,000.
- Purchase Price: $3.329 per share.
- Use of Proceeds: Working capital and general corporate purposes.
- Remaining Obligation: A second closing for 506,080 shares at a consideration of $1,684,740.29 is expected on or before February 28, 2022.
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels for the period. It focuses solely on the specific equity transaction.
Material Changes and Management Commentary
The primary material change is the execution of the Third Amendment to the Stock Purchase Agreement originally dated October 1, 2021. This amendment extended the closing date from December 31, 2021, to January 31, 2022, facilitating the initial partial closing.
Management commentary indicates that Paradigm conveyed its commitment to and belief in the long-term growth of the Company, intending to complete the full financing amount at the agreed price. The sale was made pursuant to exemptions under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933.
Investor Verification Checklist
- Verify the receipt of the remaining $1,684,740.29 from the second closing scheduled for February 28, 2022.
- Review the full text of the Third Amendment to Stock Purchase Agreement (Exhibit 10.1) for specific covenants or conditions.
- Confirm the dilution impact of the total 600,703 shares on existing shareholders once the full financing is complete.
- Monitor subsequent filings for the actual use of the $315,000 proceeds received.